INSIGHTS ON SOLID DOSE MANUFACTURING

• High Containment Single-Use FIBC For Pharmaceutical Powder Handling

  This webinar focuses on moving the HPAPI powders thru the entire process starting with chemical synthesis of the molecule to finishing in multiple solid dosage forms.

• New Technologies For Safe Powder Handling In The Bulk Pharma Industry

  The increasing toxicity and reactivity of API products and more demanding production standards have made closed powder handling an unavoidable factor and manual handling obsolete. 

• Innovations In ADC, Highly Potent Substance Containment Tech

  This webinar covers a well-designed single-use flexible enclosure system that delivers equivalent if not better containment performance than a hard-shell isolator, at a fraction of the cost.

• Hot Melt Extrusion: Improving Solubility Of Poorly Soluble Compounds

  As you create your hot melt extrusion (HME) strategy to manufacture amorphous solid dispersions (ASDs), there are several considerations around pharmaceutical applications, formulation, and processing to ensure your plan is flexible, robust, and comprehensive.

• The API Process Development System For Personnel And Product Protection

  1/27/2020

  The API Process Development System was designed to provide personnel and product protection when working with powder and liquid substances. 

• The Importance Of Automation For API Manufacturing: Bulk Handling, Dispensing, IBC Filling

  9/1/2020

  An operation required manual filling of IBCs by using a flexible isolator installed on an upper floor with large amounts of excipients (lactose and micro cellulose)> 100 kg and only a small amount of APls of a few kilos. Operation was strenuous due to the large quantity of excipients to be handled in the isolator which lead to the damage of the flexible isolator and containment breach. Several equipment and process changes allowed them to see an increase of plant productivity.

• Five Tests For Pharmaceutical Containment

  3/13/2020

  As active pharmaceutical ingredients increase in potency and become more hazardous to work with, pharmacological and chemical containment devices are required to meet containment performance targets through independent testing before use in laboratories can begin. Typically, we test containment equipment against some minimum performance standard. This is necessary to protect procedural integrity and the sensitive products undergoing processing.

• Toxic Treatments: Controlling Exposure Risks In ADC Manufacturing

  1/23/2020

  The potency and effectiveness of the ADCs are dependent upon engineered nanoparticles (ENPs), but little is known about the environmental and human health hazards posed by ENPs.

• Containment Liability: Choosing Assurance Or Insurance

  6/4/2020

  Engineering controls designed to mitigate exposure and create separation between the operator and toxic material are available in many forms, all with their own unique advantages and risks.